UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 41

of 'Approach to the patient following treatment for breast cancer'

41
TI
Breast cancer and clinical utility of CA 15-3 and CEA.
AU
Jäger W, Krämer S, Palapelas V, Norbert L
SO
Scand J Clin Lab Invest Suppl. 1995;221:87.
 
This manuscript summarizes the experiences with CA 15-3 and CEA obtained in 8,000 breast cancer patients. These markers were usually in normal range (CEA<6 micrograms/L, CA 15-3<40 U/L) before surgery and increased only before the development of distant metastases. 80% of all patients with metastases had elevated marker levels several months before or at the time of detection of metastases. Therefore CA 15-3 and CEA determinations should be used as an easy method for screening of metastases during follow-up of breast cancer patients.
AD
Department Obstetrics Gynecology, University of Erlangen-Nuremberg, Germany.
PMID